NO994506L - Fremgangsmåter og blandinger for å modulere mottagelighet for kortikosteroider - Google Patents
Fremgangsmåter og blandinger for å modulere mottagelighet for kortikosteroiderInfo
- Publication number
- NO994506L NO994506L NO994506A NO994506A NO994506L NO 994506 L NO994506 L NO 994506L NO 994506 A NO994506 A NO 994506A NO 994506 A NO994506 A NO 994506A NO 994506 L NO994506 L NO 994506L
- Authority
- NO
- Norway
- Prior art keywords
- agent
- corticosteroid
- subject
- preferred
- antagonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/820,692 US6054487A (en) | 1997-03-18 | 1997-03-18 | Methods and compositions for modulating responsiveness to corticosteroids |
US1634698A | 1998-01-30 | 1998-01-30 | |
PCT/US1998/004916 WO1998041232A2 (en) | 1997-03-18 | 1998-03-12 | Compositions for modulating responsiveness to corticosteroids |
Publications (2)
Publication Number | Publication Date |
---|---|
NO994506D0 NO994506D0 (no) | 1999-09-17 |
NO994506L true NO994506L (no) | 1999-11-17 |
Family
ID=26688484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO994506A NO994506L (no) | 1997-03-18 | 1999-09-17 | Fremgangsmåter og blandinger for å modulere mottagelighet for kortikosteroider |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP0998300A1 (bg) |
JP (1) | JP2002504091A (bg) |
KR (1) | KR20000076420A (bg) |
CN (1) | CN1269722A (bg) |
AU (1) | AU734756B2 (bg) |
BG (1) | BG103808A (bg) |
BR (1) | BR9810409A (bg) |
CA (1) | CA2282845A1 (bg) |
DE (1) | DE998300T1 (bg) |
ES (1) | ES2146192T1 (bg) |
HU (1) | HUP0104439A3 (bg) |
ID (1) | ID22975A (bg) |
IL (1) | IL131815A0 (bg) |
NO (1) | NO994506L (bg) |
NZ (1) | NZ337769A (bg) |
PL (1) | PL336464A1 (bg) |
SI (1) | SI20110A (bg) |
SK (1) | SK122199A3 (bg) |
TR (1) | TR199902615T2 (bg) |
WO (1) | WO1998041232A2 (bg) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
ZA95960B (en) * | 1994-03-14 | 1995-10-10 | Genetics Inst | Use of interleukin-12 antagonists in the treatment of autoimmune diseases |
US6830751B1 (en) | 1994-03-14 | 2004-12-14 | Genetics Institute, Llc | Use of IL-12 antagonists in the treatment of rheumatoid arthritis |
US7220717B2 (en) | 1997-08-14 | 2007-05-22 | Yeda Research And Development Company Ltd. | Interleukin-18 binding proteins, their preparation and use |
IL121860A0 (en) | 1997-08-14 | 1998-02-22 | Yeda Res & Dev | Interleukin-18 binding proteins their preparation and use |
US7704944B2 (en) | 1997-08-14 | 2010-04-27 | Yeda Research And Development Company Ltd. | Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis |
US6184210B1 (en) | 1997-10-10 | 2001-02-06 | Cytovia, Inc. | Dipeptide apoptosis inhibitors and the use thereof |
AR015966A1 (es) * | 1997-10-17 | 2001-05-30 | Smithkline Beecham Corp | Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito |
EP1516630A3 (en) * | 1997-10-31 | 2006-05-03 | Wyeth | Use of anti-il-12 antibodies in transplantation rejection |
CA2276420A1 (en) * | 1997-10-31 | 1999-05-14 | Terry Strom | Use of anti-il-12 antibodies in transplantation rejection |
WO1999025737A1 (en) * | 1997-11-19 | 1999-05-27 | Tanox Pharma B.V. | Compositions and methods for treatment of autoimmune diseases, using a monoclonal antibody to the interleukin-12 beta2-chain |
ATE295177T1 (de) * | 1998-03-16 | 2005-05-15 | Cytovia Inc | Dipeptid kaspase inhibitoren und deren verwendung |
EP1140206A4 (en) * | 1998-11-27 | 2002-04-10 | Technion Res & Dev Foundation | VACCINE BASED ON INTERFERON GAMMA INDUCTION FACTOR AND USE THEREOF FOR PROVIDING PROTECTION IMMUNITY AGAINST MULTIPLE SCLEROSIS |
EP1336654A1 (en) * | 1998-12-09 | 2003-08-20 | Protein Design Labs, Inc. | Method of treating psoriasis using anti-gamma interferon antibody |
EP1165490B1 (en) | 1999-03-16 | 2006-08-16 | Cytovia, Inc. | Substituted 2-aminobenzamide caspase inhibitors and the use thereof |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
US7883704B2 (en) | 1999-03-25 | 2011-02-08 | Abbott Gmbh & Co. Kg | Methods for inhibiting the activity of the P40 subunit of human IL-12 |
DE19915465A1 (de) * | 1999-04-06 | 2000-10-19 | Apotech Res & Dev Ltd | Verwendung eines Caspase-Inhibitors zur Proliferationshemmung von Zellen und Verwendung eines oder mehrerer Caspase-Inhibitors/en zur Behandlung von Erkrankungen beruhend auf Lymphozyten-Hyperproliferation oder zur Suppression einer Immunantwort durch Lymphozyten |
ATE363465T1 (de) | 1999-04-09 | 2007-06-15 | Cytovia Inc | Caspase inhibitoren und ihre verwendung |
IL131047A0 (en) * | 1999-07-22 | 2001-01-28 | Yeda Res & Dev | Use of il-18 inhibitors |
EA200200301A1 (ru) | 1999-08-27 | 2002-08-29 | Сайтовиэ, Инк. | ЗАМЕЩЕННЫЕ α-ГИДРОКСИКИСЛОТЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ИНГИБИРОВАНИЯ КЛЕТОЧНОЙ ГИБЕЛИ НА КЛЕТОЧНОМ ИЛИ ТКАНЕВОМ УРОВНЕ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ОБЛЕГЧЕНИЯ СОСТОЯНИЯ ПРИ ГИБЕЛИ КЛЕТОК У ЖИВОТНОГО, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАЗЛИЧНЫХ БОЛЕЗНЕЙ |
WO2001019373A2 (en) * | 1999-09-17 | 2001-03-22 | Basf Aktiengesellschaft | Methods and compositions for modulating responsiveness to corticosteroids |
US6566338B1 (en) | 1999-10-12 | 2003-05-20 | Cytovia, Inc. | Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death |
AU2001236807A1 (en) | 2000-02-10 | 2001-08-20 | Abbott Laboratories | Antibodies that bind human interleukin-18 and methods of making and using |
WO2001093909A2 (en) * | 2000-06-06 | 2001-12-13 | Glaxo Group Limited | Cancer treatment composition containing an anti-neoplastic agent and a pde4 inhibitor |
AU7250301A (en) * | 2000-06-22 | 2002-01-02 | Willy Ben Moussa Ben Mohammed | Use of glucocorticosteroids for producing a medicament to treat oligotrichia |
US20020025317A1 (en) * | 2000-07-20 | 2002-02-28 | Schering Ag | Bispecific monoclonal antibodies to IL-12 and IL-18 |
WO2002022127A1 (en) * | 2000-09-13 | 2002-03-21 | Isis Innovation Limited | Use of phosphodiesterase inhibitors for the treatment of anorectal disorders |
EP1199074A1 (en) * | 2000-09-15 | 2002-04-24 | Warner-Lambert Company | Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
EP1188438A1 (en) * | 2000-09-15 | 2002-03-20 | Warner-Lambert Company | Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production |
EE05534B1 (et) * | 2001-01-29 | 2012-04-16 | Applied Research Systems Ars Holding N.V. | IL-18 inhibiitorite kasutamine ravimi valmistamiseks kardiomopaatia raviks ja/v?i ennetamiseks |
DK1425028T3 (da) * | 2001-05-16 | 2010-03-01 | Yeda Res & Dev | Anvendelse af IL-18 inhibitorer til behandling eller forebyggelse af sepsis |
ATE464068T1 (de) | 2001-06-26 | 2010-04-15 | Amgen Fremont Inc | Antikörper gegen opgl |
WO2003030823A2 (en) * | 2001-10-05 | 2003-04-17 | Combinatorx, Incorporated | Combinations for the treatment of immunoinflammatory disorders |
JP2003342196A (ja) * | 2002-05-31 | 2003-12-03 | Mukku:Kk | 静脈注射用組成物、その製造法およびその製剤 |
AR041386A1 (es) * | 2002-09-24 | 2005-05-18 | Combinatorx Inc | Metodos y reactivos para el tratamiento de enfermedades y trastornos asociados con niveles aumentados de citoquinas proinflamatorias |
WO2004028545A1 (en) * | 2002-09-25 | 2004-04-08 | Astrazeneca Ab | A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES |
US20060083714A1 (en) * | 2003-01-27 | 2006-04-20 | Warner James M | Combination of a pde iv inhibitor and a tnf-alpha antagonist |
US20050100965A1 (en) | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
EP1752159A4 (en) * | 2004-05-17 | 2009-07-01 | Univ Keio | MEDICAL COMPOSITION AND THERAPEUTIC PROCEDURE |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
DK1808446T3 (da) * | 2004-07-16 | 2012-05-14 | Atsuo Sekiyama | IL-18-receptor-antagonist og farmaceutisk sammensætning indeholdende antagonisten |
CA2584169A1 (en) * | 2004-10-13 | 2006-04-20 | Kyowa Hakko Kogyo Co., Ltd. | Remedies/preventives for chronic skin disease |
ES2384641T3 (es) | 2005-07-14 | 2012-07-10 | Lithera, Inc. | Formulación lipolítica que potencia la liberación mantenida para el tratamiento localizado del tejido adiposo |
JP2010506941A (ja) * | 2006-10-17 | 2010-03-04 | リセラ,インク. | 甲状腺眼症の治療のための方法、組成物及び製剤 |
CN104524567A (zh) | 2007-01-16 | 2015-04-22 | 阿布维公司 | 用于治疗银屑病的方法 |
WO2008121301A1 (en) | 2007-03-29 | 2008-10-09 | Abbott Laboratories | Crystalline anti-human il-12 antibodies |
KR20100126515A (ko) | 2008-03-18 | 2010-12-01 | 아보트 러보러터리즈 | 건선의 치료방법 |
US9132084B2 (en) | 2009-05-27 | 2015-09-15 | Neothetics, Inc. | Methods for administration and formulations for the treatment of regional adipose tissue |
EA201270784A1 (ru) | 2010-11-24 | 2013-04-30 | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" | Монотерапевтические композиции селективного липофильного и бета-агониста длительного действия и способы косметического лечения ожирения и контурного выпячивания |
WO2015063669A1 (en) | 2013-10-30 | 2015-05-07 | Wockhardt Limited | Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof |
AU2022353032A1 (en) * | 2021-09-22 | 2024-03-28 | Iolyx Therapeutics, Inc. | Methods of treating ocular inflammatory diseases |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3320125A (en) * | 1964-04-28 | 1967-05-16 | Merck & Co Inc | Inhalation aerosol composition |
GB2235626B (en) * | 1989-09-08 | 1994-02-09 | Glaxo Group Ltd | Inhalation medicaments for treating respiratory disorders |
IL104068A (en) * | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant |
GB9202519D0 (en) * | 1992-02-06 | 1992-03-25 | Glaxo Group Ltd | Medicaments |
MX9304585A (es) * | 1992-07-31 | 1994-03-31 | Glaxo Group Ltd | Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata. |
GB9426252D0 (en) * | 1994-12-24 | 1995-02-22 | Glaxo Group Ltd | Pharmaceutical composition |
JP3573213B2 (ja) * | 1995-04-14 | 2004-10-06 | グラクソ、ウェルカム、インコーポレーテッド | ベクロメタゾンジプロピオネート用計量投与用吸入器 |
-
1998
- 1998-03-12 KR KR1019997008524A patent/KR20000076420A/ko not_active Application Discontinuation
- 1998-03-12 EP EP98912929A patent/EP0998300A1/en not_active Withdrawn
- 1998-03-12 PL PL98336464A patent/PL336464A1/xx unknown
- 1998-03-12 AU AU67604/98A patent/AU734756B2/en not_active Ceased
- 1998-03-12 CA CA002282845A patent/CA2282845A1/en not_active Abandoned
- 1998-03-12 DE DE0998300T patent/DE998300T1/de active Pending
- 1998-03-12 JP JP54063398A patent/JP2002504091A/ja active Pending
- 1998-03-12 IL IL13181598A patent/IL131815A0/xx unknown
- 1998-03-12 ES ES98912929T patent/ES2146192T1/es active Pending
- 1998-03-12 SI SI9820032A patent/SI20110A/sl unknown
- 1998-03-12 NZ NZ337769A patent/NZ337769A/xx unknown
- 1998-03-12 TR TR1999/02615T patent/TR199902615T2/xx unknown
- 1998-03-12 BR BR9810409-8A patent/BR9810409A/pt not_active IP Right Cessation
- 1998-03-12 WO PCT/US1998/004916 patent/WO1998041232A2/en not_active Application Discontinuation
- 1998-03-12 CN CN98805124A patent/CN1269722A/zh active Pending
- 1998-03-12 HU HU0104439A patent/HUP0104439A3/hu unknown
- 1998-03-12 ID IDW991185A patent/ID22975A/id unknown
- 1998-03-12 SK SK1221-99A patent/SK122199A3/sk unknown
-
1999
- 1999-09-17 NO NO994506A patent/NO994506L/no unknown
- 1999-10-13 BG BG103808A patent/BG103808A/bg unknown
Also Published As
Publication number | Publication date |
---|---|
CA2282845A1 (en) | 1998-09-24 |
KR20000076420A (ko) | 2000-12-26 |
HUP0104439A2 (hu) | 2002-04-29 |
BR9810409A (pt) | 2000-08-22 |
PL336464A1 (en) | 2000-06-19 |
NO994506D0 (no) | 1999-09-17 |
EP0998300A1 (en) | 2000-05-10 |
BG103808A (bg) | 2000-07-31 |
CN1269722A (zh) | 2000-10-11 |
TR199902615T2 (xx) | 2000-03-21 |
AU734756B2 (en) | 2001-06-21 |
AU6760498A (en) | 1998-10-12 |
NZ337769A (en) | 2002-09-27 |
WO1998041232A2 (en) | 1998-09-24 |
ES2146192T1 (es) | 2000-08-01 |
IL131815A0 (en) | 2001-03-19 |
HUP0104439A3 (en) | 2002-08-28 |
ID22975A (id) | 1999-12-23 |
WO1998041232A3 (en) | 2000-10-05 |
SK122199A3 (en) | 2000-12-11 |
DE998300T1 (de) | 2001-03-01 |
SI20110A (sl) | 2000-06-30 |
JP2002504091A (ja) | 2002-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO994506L (no) | Fremgangsmåter og blandinger for å modulere mottagelighet for kortikosteroider | |
WO2001019373A3 (en) | Methods and compositions for modulating responsiveness to corticosteroids | |
Adamopoulos et al. | Pituitary-testicular interrelationships in mumps orchitis and other viral infections | |
Axelrod et al. | Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout | |
Williamson et al. | Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. | |
Burris et al. | A low sperm concentration does not preclude fertility in men with isolated hypogonadotropic hypogonadism after gonadotropin therapy | |
Puig-Domingo et al. | Melatonin-related hypogonadotropic hypogonadism | |
MANN et al. | Long‐term administration of corticosteroids in myasthenia gravis | |
Durham et al. | Immunotherapy and allergic inflammation. | |
Reinberg et al. | Annual variation in semen characteristics and plasma hormone levels in men undergoing vasectomy | |
Chen et al. | Persistent effect of in utero meso-2, 3-dimercaptosuccinic acid (DMSA) on immune function and lead-induced immunotoxicity | |
KAY et al. | Immunofluorescent techniques in clinical diagnosis of cutaneous disease | |
Nissinen et al. | Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis | |
Brooks-Asplund et al. | Hormonal modulation of interleukin-6, tumor necrosis factor and associated receptor secretion in postmenopausal women | |
De Merieux et al. | Treatment of Behcet's syndrome with levamisole | |
JP2006516617A (ja) | アポトーシスを増強させるための、il−6アンタゴニストとステロイドの併用 | |
Lue et al. | Recombinant human interleukin 6 (rhIL-6) promotes the terminal differentiation of in vivo-activated human B cells into antibody-secreting cells | |
Sauer et al. | Rare occurrence of ovarian hyperstimulation syndrome in oocyte donors | |
Kreisler et al. | Multiple sclerosis, interferon beta and clinical thyroid dysfunction | |
CA2296409A1 (en) | Agents comprising midkine or its inhibitor as active ingredient | |
Shapira et al. | Tetracycline inhibits Porphyromonas gingivalis lipopolysaccharide‐induced lesions in vivo and TNFα processing in vitro | |
Bouzehouane et al. | Treatment of moderate to severe orbitopathy: Current modalities and perspectives | |
De Almeida et al. | Dexamethasone therapy of infertile men with sperm autoantibodies: immunological and sperm follow-up. | |
Nutku et al. | Evidence for expression of eosinophil-associated IL-12 messenger RNA and immunoreactivity in bronchial asthma | |
Heiligenhaus et al. | Eosinophil granule proteins expressed in ocular cicatricial pemphigoid |